-
2023-507890-17-00
5
2021-02-22
Anemia associated with myeloproliferative neoplasm (MPN)-associated my
-
2022-503072-84-00
5
2021-02-13
stage IIIa cardiac AL amyloidosis
-
2022-503073-11-00
5
2021-02-13
Stage IIIb cardiac AL amyloidosis
-
2024-514502-31-00
5
2021-01-11
Prurigo Nodularis
-
2023-504830-23-00
5
2020-12-16
B-cell Lymphoma
-
2022-501645-70-00
5
2020-11-25
Crohns Disease
-
2022-502611-10-00
5
2020-11-24
Primary Progressive Multiple Sclerosis (PPMS)
-
2023-509358-72-00
5
2020-11-23
Diffuse large B-cell lymphoma
-
2023-507153-16-00
5
2020-11-18
Higher-Risk Myelodysplastic Syndrome
-
2023-505852-23-00
5
2020-11-12
High risk recurrent prostate cancer previously treated with radical pr
-
2022-502052-30-00
5
2020-10-27
Unresectable Esophageal Squamous Cell Carcinoma
-
2023-510390-33-00
5
2020-10-23
HER2-negative breast cancer patients with high relapse risk after
stan
-
2023-505830-89-00
6
2020-08-05
metastatic castrate resistant prostate cancer (mCRPC)
-
2024-511832-29-00
4
2020-08-05
High risk adenocarcinoma of the prostate after radical prostatectomy
(
-
2024-515669-32-00
5
2020-06-30
Pulmonary arterial hypertension
-
2023-508292-37-00
5
2020-03-06
Cardiovascular Disease
-
2023-509908-15-00
10
2020-01-20
Mantle Cell Lymphoma
-
2022-502478-18-00
4
2019-12-20
Acute Myeloid Leukemia (AML)
-
2024-510626-89-00
5
2019-11-18
Non-Alcoholic Steatohepatitis (NASH)
-
2023-503670-21-00
5
2019-08-28
Patients with newly diagnosed AML and intermediate- or adverse-risk ge
-
2024-515375-35-00
4
2019-08-26
Untreated patients with higher risk MDS and oligoblastic AML eligible
-
2023-507582-25-00
5
2019-08-02
Malignant Extracranial Germ Cell Tumours (MGCT)
-
2023-506830-66-00
4
2019-05-29
SGA - small for gestational age children
-
2023-510357-42-00
5
2019-05-22
hormone receptor (HR)-positive, HER2-negative,
early breast cancer (EB